Sangamo Therapeutics (SGMO) Downgraded to Hold at Zacks Investment Research
Zacks Investment Research lowered shares of Sangamo Therapeutics (NASDAQ:SGMO) from a buy rating to a hold rating in a research note published on Friday.
According to Zacks, “Sangamo Therapeutics, Inc. is a biotechnology company. It focuses on research and development of genomic therapies as well as develops medicines for patient with genetic diseases. The Company’s product pipeline includes SB-525, SB-FIX, SB-318, SB-913, SB-728-T and SB-728-HSPC. Sangamo Therapeutics Inc., formerly known as Sangamo BioSciences Inc., is based in Richmond, United States. “
A number of other equities research analysts also recently weighed in on SGMO. Jefferies Group reiterated a buy rating and issued a $18.00 price target on shares of Sangamo Therapeutics in a report on Thursday, September 14th. Piper Jaffray Companies upgraded Sangamo Therapeutics from a neutral rating to an overweight rating and set a $19.00 price target for the company in a report on Wednesday, November 15th. Wedbush reiterated a hold rating and issued a $6.00 price target on shares of Sangamo Therapeutics in a report on Wednesday, November 15th. Barclays initiated coverage on Sangamo Therapeutics in a report on Wednesday, November 22nd. They issued an overweight rating and a $20.00 price target for the company. Finally, BidaskClub upgraded Sangamo Therapeutics from a hold rating to a buy rating in a report on Friday, December 29th. Three equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The stock has an average rating of Buy and an average target price of $18.83.
Sangamo Therapeutics (NASDAQ:SGMO) last issued its quarterly earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.19) by $0.04. Sangamo Therapeutics had a negative return on equity of 31.81% and a negative net margin of 157.66%. The business had revenue of $11.81 million during the quarter, compared to the consensus estimate of $10.37 million. During the same period in the previous year, the business earned ($0.27) EPS. The business’s quarterly revenue was up 333.0% on a year-over-year basis. equities research analysts anticipate that Sangamo Therapeutics will post -0.73 EPS for the current fiscal year.
In related news, VP Curt A. Herberts III sold 15,000 shares of the business’s stock in a transaction that occurred on Wednesday, January 3rd. The stock was sold at an average price of $17.26, for a total transaction of $258,900.00. Following the completion of the transaction, the vice president now owns 13,015 shares in the company, valued at approximately $224,638.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Curt A. Herberts III sold 11,803 shares of the business’s stock in a transaction that occurred on Monday, December 4th. The shares were sold at an average price of $18.00, for a total value of $212,454.00. Following the transaction, the vice president now owns 27,636 shares of the company’s stock, valued at approximately $497,448. The disclosure for this sale can be found here. Insiders sold a total of 53,433 shares of company stock valued at $894,146 over the last quarter. Company insiders own 5.50% of the company’s stock.
A number of large investors have recently added to or reduced their stakes in the stock. Neuberger Berman Group LLC acquired a new position in Sangamo Therapeutics during the 3rd quarter valued at approximately $315,000. Cubist Systematic Strategies LLC boosted its position in Sangamo Therapeutics by 143.9% during the 3rd quarter. Cubist Systematic Strategies LLC now owns 19,942 shares of the biopharmaceutical company’s stock valued at $299,000 after purchasing an additional 11,766 shares during the period. Point72 Asset Management L.P. boosted its position in Sangamo Therapeutics by 93.8% during the 3rd quarter. Point72 Asset Management L.P. now owns 693,300 shares of the biopharmaceutical company’s stock valued at $10,400,000 after purchasing an additional 335,595 shares during the period. Jane Street Group LLC acquired a new position in Sangamo Therapeutics during the 3rd quarter valued at approximately $624,000. Finally, California State Teachers Retirement System boosted its position in Sangamo Therapeutics by 5.0% during the 3rd quarter. California State Teachers Retirement System now owns 132,741 shares of the biopharmaceutical company’s stock valued at $1,991,000 after purchasing an additional 6,360 shares during the period. Institutional investors and hedge funds own 64.33% of the company’s stock.
Sangamo Therapeutics Company Profile
Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.